Repligen (RGEN) AI Stock Analysis

• Market Cap: $8.39B
• Dividend Yield: N/A
• Average Volume (3M): 1.07M
• Price to Earnings (P/E): 6775.5
• Beta (1Y): 1.26
• Revenue Growth: 11.74%
• EPS Growth: N/A
• Country: US
• Employees: 1,778
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.46
• Shares Outstanding: 56,257,618
• 10 Day Avg. Volume: 1,272,079
• 30 Day Avg. Volume: 1,072,075
• PEG Ratio: 1.84
• Price to Book (P/B): 4.08
• Price to Sales (P/S): 12.69
• P/FCF Ratio: 56.51
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 11.15
• Enterprise Value/Gross Profit: 23.03
• Enterprise Value/Ebitda: 55.46
• 1Y Price Target: $183.36
• Price Target Upside: 23.01% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 15

• Rating: 63 Neutral
• Price Target: $162.00 ▲(8.68% Upside)

Repligen's overall stock score is driven by strong earnings call performance and positive technical indicators. However, the high P/E ratio and profitability challenges weigh down the score. The company's ability to sustain growth and improve profitability will be key to enhancing its stock performance.

Positive Factors

Organic Growth

Strong organic growth across all franchises indicates robust demand and effective market strategies, supporting long-term revenue expansion.

Geographical Expansion

Significant growth in Asia Pacific and other regions highlights successful international expansion, enhancing global market presence and diversification.

Gross Margin Improvement

Improved gross margins reflect operational efficiencies and cost management, contributing to sustainable profitability and competitive positioning.

Negative Factors

Profitability Challenges

Negative profit margins indicate ongoing profitability issues, which could hinder financial stability and shareholder returns if not addressed.

Cash Flow Management

Declining free cash flow growth suggests potential inefficiencies in cash management, which could impact the company's ability to fund operations and growth.

China Market Challenges

Challenges in the China market may limit growth opportunities and affect revenue, highlighting the need for strategic adjustments in this key region.

Repligen Business Overview & Revenue Model

Company Description

Repligen Corporation (RGEN) is a bioprocessing company that specializes in developing and manufacturing high-purity products for the biopharmaceutical industry. The company operates primarily in the life sciences sector, focusing on enabling the production of biologic drugs through its innovative technologies and products. Repligen's core offerings include chromatography resins, filtration systems, and various tools that enhance the efficiency and effectiveness of bioprocessing workflows. Its products are utilized in the production of monoclonal antibodies, therapeutic proteins, and vaccines, catering to a growing demand in the biopharmaceutical market.

How the Company Makes Money

Repligen generates revenue primarily through the sale of its bioprocessing products and technologies. Key revenue streams include the sale of chromatography resins, filtration products, and other consumables used in biomanufacturing processes. The company also derives income from its services related to product development and customer support. Significant partnerships with leading biopharmaceutical companies enhance its market presence and contribute to its earnings by ensuring consistent demand for its products. Additionally, Repligen's focus on innovation and expansion into new markets helps to drive growth and diversify its revenue base.

Repligen Financial Statement Overview

Summary

Repligen shows a mixed financial performance with strong balance sheet and operational cash flow, but faces challenges in profitability and growth. The company maintains a strong equity position and low leverage, yet needs to address its declining net income and EBIT margins to improve its financial health and investor confidence.

Income Statement

Repligen's revenue shows a marginal growth from the previous year, but has declined from 2022. The gross profit margin for TTM is approximately 54.88%, indicating decent cost management. However, the company is experiencing negative net income and EBIT margins, highlighting profitability challenges. The EBITDA margin is positive at 13.80%, suggesting some operational efficiency.

Balance Sheet

The company's balance sheet is relatively strong with a debt-to-equity ratio of approximately 0.34, indicating low leverage. The equity ratio is around 69.60%, reflecting a healthy balance of equity financing. However, the return on equity is negative due to net losses, which is a concern for investors seeking returns.

Cash Flow

Repligen's cash flow statement shows a decrease in free cash flow compared to the annual report, with a negative free cash flow growth rate. The operating cash flow to net income ratio is negative due to the net loss, but operating cash flow remains positive, which indicates underlying operational strength despite profitability concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	673.96M	634.44M	632.36M	801.54M	670.53M	366.26M
Gross Profit	326.42M	274.64M	308.83M	455.71M	391.25M	209.63M
EBITDA	135.55M	82.10M	127.77M	246.93M	211.56M	101.62M
Net Income	-13.83M	-25.51M	35.60M	185.96M	128.29M	59.93M
Balance Sheet
Total Assets	2.90B	2.83B	2.83B	2.53B	2.36B	1.90B
Cash, Cash Equivalents and Short-Term Investments	708.86M	757.36M	751.32M	623.76M	603.81M	717.29M
Total Debt	686.06M	686.25M	711.80M	422.96M	366.05M	275.42M
Total Liabilities	839.89M	856.95M	866.34M	620.90M	608.29M	373.74M
Stockholders Equity	2.06B	1.97B	1.96B	1.91B	1.75B	1.53B
Cash Flow
Free Cash Flow	103.81M	142.49M	74.93M	38.74M	47.74M	36.28M
Operating Cash Flow	132.11M	175.39M	113.92M	172.08M	119.02M	62.63M
Investing Cash Flow	-152.57M	-86.38M	-123.28M	-233.24M	-221.17M	-201.38M
Financing Cash Flow	-83.32M	-82.90M	248.96M	-13.34M	961.00K	305.92M

Repligen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 149.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGEN, the sentiment is Positive. The current price of 149.06 is below the 20-day moving average (MA) of 152.48, above the 50-day MA of 135.46, and above the 200-day MA of 135.03, indicating a neutral trend. The MACD of 4.59 indicates Positive momentum. The RSI at 51.94 is Neutral, neither overbought nor oversold. The STOCH value of 7.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RGEN.

Repligen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	―	$5.19B	44.80	8.30%	―	11.49%	-2.89%
TFX	―	$5.50B	29.30	4.36%	1.09%	1.11%	-23.73%
RGEN	―	$8.39B	6,775.45	0.08%	―	11.74%	―
STVN	―	$6.88B	47.10	9.55%	0.24%	5.95%	7.73%
BLCO	―	$5.29B	―	-4.69%	―	6.23%	17.53%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATR	―	$7.64B	18.59	15.79%	1.58%	2.50%	25.05%

Repligen Corporate Events

Repligen Corporation Reports Strong Q3 2025 Results

Repligen Corporation is a global life sciences company that specializes in developing and commercializing innovative bioprocessing technologies and systems, primarily serving biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs). The company is headquartered in Waltham, Massachusetts, with manufacturing sites in the U.S. and Europe.

Repligen Appoints Violetta Hughes as Chief Accounting Officer

On September 2, 2025, Repligen Corporation announced the appointment of Violetta Hughes as the new Chief Accounting Officer, effective September 1, 2025. This strategic move aims to enhance the company’s financial reporting infrastructure and compliance with the Sarbanes–Oxley Act. Ms. Hughes, a seasoned finance executive with over 25 years of experience, will replace Jason K. Garland, who will continue as the Chief Financial Officer focusing on corporate strategy and growth. Her extensive background in financial governance and SOX compliance is expected to bring significant improvements to Repligen’s financial transparency and strategic decision-making processes.

The most recent analyst rating on (RGEN) stock is a Buy with a $207.00 price target. To see the full list of analyst forecasts on Repligen stock, see the RGEN Stock Forecast page.

Repligen’s Earnings Call Highlights Robust Growth

Repligen’s recent earnings call showcased a robust performance, highlighting significant growth in non-COVID areas, particularly in biopharma and chromatography sectors. Despite facing challenges from the gene therapy platform and muted biotech orders, the company’s overall financial health and strategic initiatives, coupled with increased guidance, suggest a positive outlook for the future.

Repligen Corporation Reports Strong Q2 2025 Growth

Repligen Corporation is a global life sciences company specializing in bioprocessing technologies, serving biopharmaceutical drug developers and contract development and manufacturing organizations worldwide. In its second quarter of 2025, Repligen reported a revenue of $182 million, marking a 15% year-over-year increase, with a notable 17% organic growth excluding COVID-related revenue. Orders grew by over 20% year-over-year, reflecting strong demand across its portfolio. The company has raised its revenue guidance for the full year to a range of $715 to $735 million, indicating a 12.5% to 15.5% year-over-year non-COVID organic growth. Key highlights from the quarter include broad-based revenue strength across all franchises, with consumables and capital equipment showing significant growth. Repligen also launched a new product, the ProConnex® MixOne, and published its 2024 Sustainability report. Financially, the company achieved a GAAP net income of $15 million, up from $6 million the previous year, and an adjusted net income of $21 million. Looking ahead, Repligen remains optimistic about its growth prospects, despite facing headwinds from new modalities, and continues to focus on executing its strategic initiatives to drive further success.